Administrative Core - IPCAVD -? E-DNA + Env protein Vaccination for HIV The goal of this program to produce an enhanced E/P delivered gene adjuvanted DNA vaccine (E-DNA) and combine this with a highly novel polyvalent A, B, C, A/E recombinant protein boost (PPB) as a vaccine platform. The EP focus of this application is to utilize novel surface delivery. By this combination we hypothesize that we will generate an improved spectrum of T and B anti HIV immune responses compared to current HIV vaccine modalities. This project builds on a major innovations and accomplishments by the members of this team that have led to this proposal. The team has worked together productively for multiple years. Furthermore they have an outstanding track record of productivity working with the HVTN. The inclusion of CHAVI investigators as part of the preclinical development immune analysis is a major strength of the program. There are 3 highly interrelated, translational focused, exceptionally novel projects which build on a strong track record of accomplishment together that comprise this program. They are supported by a highly respected, important protein core as well as seasoned administrative core. The Administrative core (AC) is responsible for overall program performance, sample distribution, programmatic oversight, HVTN and NIH Programmatic interactions and for recommending SAB members for program review. The AC will arrange the annual SAB meeting and put in place a work plan to act on the SAB?s suggestions with guidance of NIH program. The external SAB will be put in place upon notification of award of this program. The administrative core will arrange team calls for open data discussion, and time line review, arrange monthly calls with NIH program, arrange monthly calls to review progress with the PI and teams, arrange biannual data review meetings and provide yearly written reports on progress for program feedback as well as facilitate publication of findings and scientific meeting attendance for result reporting. The AC will also update the HVTN on a quarterly basis relative to programmatic goals. We have an established HVTN development team to facilitate this process and this will be expanded based on this application being funded (HVTN letter).

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
1U19AI109646-01A1
Application #
8892528
Study Section
Special Emphasis Panel (ZAI1-EC-A (J1))
Project Start
Project End
2016-02-29
Budget Start
2015-03-01
Budget End
2016-02-29
Support Year
1
Fiscal Year
2015
Total Cost
$197,316
Indirect Cost
$20,224
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Schultheis, Katherine; Smith, Trevor R F; Kiosses, William B et al. (2018) Delineating the Cellular Mechanisms Associated with Skin Electroporation. Hum Gene Ther Methods 29:177-188
Xu, Ziyang; Wise, Megan C; Choi, Hyeree et al. (2018) Synthetic DNA delivery by electroporation promotes robust in vivo sulfation of broadly neutralizing anti-HIV immunoadhesin eCD4-Ig. EBioMedicine 35:97-105
Wang, Shixia; Chou, Te-Hui; Hackett, Anthony et al. (2017) Screening of primary gp120 immunogens to formulate the next generation polyvalent DNA prime-protein boost HIV-1 vaccines. Hum Vaccin Immunother 13:2996-3009
Fisher, P D; Brambila, C J; McCoy, J R et al. (2017) Adipose tissue: a new target for electroporation-enhanced DNA vaccines. Gene Ther 24:757-767
Tebas, Pablo; Roberts, Christine C; Muthumani, Kar et al. (2017) Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine - Preliminary Report. N Engl J Med :
Smith, Trevor R F; Schultheis, Katherine; Broderick, Kate E (2017) Nucleic acid-based vaccines targeting respiratory syncytial virus: Delivering the goods. Hum Vaccin Immunother 13:2626-2629
Smith, Trevor R F; Schultheis, Katherine; Morrow, Matthew P et al. (2017) Development of an intradermal DNA vaccine delivery strategy to achieve single-dose immunity against respiratory syncytial virus. Vaccine 35:2840-2847
Ake, Julie A; Schuetz, Alexandra; Pegu, Poonam et al. (2017) Safety and Immunogenicity of PENNVAX-G DNA Prime Administered by Biojector 2000 or CELLECTRA Electroporation Device With Modified Vaccinia Ankara-CMDR Boost. J Infect Dis 216:1080-1090
Griffiths, Kristin L; Villarreal, Daniel O; Weiner, David B et al. (2016) A novel multivalent tuberculosis vaccine confers protection in a mouse model of tuberculosis. Hum Vaccin Immunother 12:2649-2653
Kutzler, M A; Wise, M C; Hutnick, N A et al. (2016) Chemokine-adjuvanted electroporated DNA vaccine induces substantial protection from simian immunodeficiency virus vaginal challenge. Mucosal Immunol 9:13-23

Showing the most recent 10 out of 14 publications